School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong.
Am J Hypertens. 2013 Jul;26(7):931-8. doi: 10.1093/ajh/hpt049. Epub 2013 Apr 16.
International guidelines recommending antihypertensive prescriptions for the management of hypertension have been published in the past decade. Beta-blocker use was discouraged by a significant body of evidence and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) were found more effective among younger patients. This study aims to evaluate the trends in prescription profiles in a large Chinese population because patterns of antihypertensive agent dispensation represent important information for physicians and policymakers.
From clinical databases consisting of all patient records in the public health-care system of Hong Kong, we examined all antihypertensive prescriptions according to the drug classes (thiazide diuretics, alpha-blockers, beta-blockers, calcium channel blockers (CCBs), ACEIs, ARBs, fixed-dose combinations, and polytherapy (2, ≥3)) between 2001 and 2010. We retrieved >6.3 million prescription episodes for 223,287 patients.
The average age of the patients was 59.9 years (SD = 17.6), and 54.8% were women. According to prescription episodes, the most commonly prescribed medications were beta-blockers (31.7%) and CCBs (29.2%), followed by ACEIs (13.9%), thiazide diuretics (5.0%), and alpha-blockers (4.5%). Between 2001 and 2010, the prescription proportions of beta-blockers decreased from 41.5% to 21.5%, whereas that of ARBs increased from 0.5% to 1.0% (P < 0.001, χ(2) test for trend). It was found that the decline of beta-blockers (71.0% to 35.4%) and increase in ARB prescriptions (0.4% to 1.0%) were particularly marked among younger subjects aged <55 years.
These findings provided information on the prescription patterns of antihypertensive agents in a large Chinese population. It sets a future research direction to study the various reasons influencing these drug class-specific trends.
过去十年间,国际上发布了多项指南,推荐使用降压药物来治疗高血压。大量证据表明,β受体阻滞剂的使用效果不佳,血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)在年轻患者中的疗效更为显著。本研究旨在评估中国这一大人群中降压药物处方的变化趋势,因为降压药物的使用模式为医生和决策者提供了重要信息。
我们从香港公共医疗系统的所有患者病历组成的临床数据库中,根据药物类别(噻嗪类利尿剂、α受体阻滞剂、β受体阻滞剂、钙通道阻滞剂(CCB)、ACEI、ARB、固定剂量联合用药和多药治疗(2 种、≥3 种)),分析了 2001 年至 2010 年间的所有降压药物处方。共检索到 630 多万例 223287 名患者的处方记录。
患者的平均年龄为 59.9 岁(标准差=17.6),54.8%为女性。根据处方记录,最常用的药物为β受体阻滞剂(31.7%)和 CCB(29.2%),其次是 ACEI(13.9%)、噻嗪类利尿剂(5.0%)和α受体阻滞剂(4.5%)。2001 年至 2010 年间,β受体阻滞剂的处方比例从 41.5%降至 21.5%,而 ARB 的处方比例从 0.5%增至 1.0%(P<0.001,趋势性 χ2检验)。结果发现,β受体阻滞剂(从 71.0%降至 35.4%)和 ARB 处方(从 0.4%增至 1.0%)的降幅在年龄<55 岁的年轻患者中更为显著。
本研究提供了中国大人群中降压药物处方模式的信息,为研究影响这些具体药物类别的趋势的各种原因指明了未来的研究方向。